CN106661098B - 抗人乳头瘤病毒16 e7的t细胞受体 - Google Patents

抗人乳头瘤病毒16 e7的t细胞受体 Download PDF

Info

Publication number
CN106661098B
CN106661098B CN201580031789.XA CN201580031789A CN106661098B CN 106661098 B CN106661098 B CN 106661098B CN 201580031789 A CN201580031789 A CN 201580031789A CN 106661098 B CN106661098 B CN 106661098B
Authority
CN
China
Prior art keywords
seq
leu
tcr
ser
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580031789.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN106661098A (zh
Inventor
克里斯蒂安·S·欣里西斯
史蒂文·A·罗森伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to CN202110399056.9A priority Critical patent/CN113150112B/zh
Publication of CN106661098A publication Critical patent/CN106661098A/zh
Application granted granted Critical
Publication of CN106661098B publication Critical patent/CN106661098B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
CN201580031789.XA 2014-05-29 2015-05-29 抗人乳头瘤病毒16 e7的t细胞受体 Active CN106661098B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110399056.9A CN113150112B (zh) 2014-05-29 2015-05-29 抗人乳头瘤病毒16 e7的t细胞受体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004335P 2014-05-29 2014-05-29
US62/004,335 2014-05-29
PCT/US2015/033129 WO2015184228A1 (en) 2014-05-29 2015-05-29 Anti-human papillomavirus 16 e7 t cell receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110399056.9A Division CN113150112B (zh) 2014-05-29 2015-05-29 抗人乳头瘤病毒16 e7的t细胞受体

Publications (2)

Publication Number Publication Date
CN106661098A CN106661098A (zh) 2017-05-10
CN106661098B true CN106661098B (zh) 2021-05-04

Family

ID=53396593

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580031789.XA Active CN106661098B (zh) 2014-05-29 2015-05-29 抗人乳头瘤病毒16 e7的t细胞受体
CN202110399056.9A Active CN113150112B (zh) 2014-05-29 2015-05-29 抗人乳头瘤病毒16 e7的t细胞受体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110399056.9A Active CN113150112B (zh) 2014-05-29 2015-05-29 抗人乳头瘤病毒16 e7的t细胞受体

Country Status (21)

Country Link
US (4) US10174098B2 (OSRAM)
EP (3) EP4609876A2 (OSRAM)
JP (5) JP6742991B2 (OSRAM)
KR (2) KR102618267B1 (OSRAM)
CN (2) CN106661098B (OSRAM)
AU (5) AU2015266818B2 (OSRAM)
BR (1) BR112016027805A2 (OSRAM)
CA (1) CA2950192A1 (OSRAM)
CY (1) CY1122790T1 (OSRAM)
DK (1) DK3149031T3 (OSRAM)
ES (1) ES2784237T3 (OSRAM)
HR (1) HRP20200376T1 (OSRAM)
IL (3) IL290655B2 (OSRAM)
LT (1) LT3149031T (OSRAM)
MX (2) MX375379B (OSRAM)
PL (1) PL3149031T3 (OSRAM)
PT (1) PT3149031T (OSRAM)
SA (1) SA516380394B1 (OSRAM)
SI (1) SI3149031T1 (OSRAM)
SM (1) SMT202000143T1 (OSRAM)
WO (1) WO2015184228A1 (OSRAM)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4609876A2 (en) * 2014-05-29 2025-09-03 The United States of America, as represented by the Secretary, Department of Health and Human Services Anti-human papillomavirus 16 e7 t cell receptors
WO2016179006A1 (en) 2015-05-01 2016-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
EP4212547A1 (en) 2015-12-03 2023-07-19 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
ES2912269T3 (es) 2016-09-27 2022-05-25 Cero Therapeutics Inc Moléculas de receptor de engullimiento quimérico
KR20190062505A (ko) * 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
US12269859B2 (en) * 2016-12-02 2025-04-08 Angeles Therapeutics, Inc. Synthetic immune receptors and methods of use thereof
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CN110650975B (zh) * 2017-05-15 2024-04-05 美国卫生和人力服务部 双顺反子嵌合抗原受体及其用途
IL299348B2 (en) * 2017-06-28 2025-05-01 Regeneron Pharma Antigen-binding proteins against human papillomavirus and methods of using them
CA3073421A1 (en) 2017-09-26 2019-04-04 Daniel Mark COREY Chimeric engulfment receptor molecules and methods of use
FI3688027T3 (fi) 2017-09-29 2025-12-09 Us Health Mutatoidun p53:n tunnistavia t-solureseptoreita
EP3692063A1 (en) * 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
IL273698B2 (en) * 2017-10-05 2025-07-01 Us Health Methods for selectively expanding cells expressing a tcr with a murine constant region
KR20200079312A (ko) 2017-11-06 2020-07-02 에디타스 메디신, 인코포레이티드 면역요법을 위한 t 세포 내 cblb의 crispr-cas9 편집 방법, 조성물 및 성분
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
EP3749770B9 (en) 2018-02-09 2025-12-17 The U.S.A. as represented by the Secretary, Department of Health and Human Services Tethered interleukin-15 and interleukin-21
JP7444781B2 (ja) 2018-03-28 2024-03-06 セロ・セラピューティクス・インコーポレイテッド 細胞免疫療法組成物およびその使用
WO2019191334A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
CA3093969A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
KR102764123B1 (ko) * 2018-04-05 2025-02-05 주노 쎄러퓨티크스 인코퍼레이티드 Τ 세포 수용체 및 이를 발현하는 조작된 세포
WO2019195491A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
JP7589047B2 (ja) 2018-04-05 2024-11-25 ジュノー セラピューティクス インコーポレイテッド 組換え受容体を発現する細胞の作製方法および関連組成物
US12415845B2 (en) 2018-04-24 2025-09-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
EP3810780A1 (en) * 2018-06-22 2021-04-28 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
SG11202101204TA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
EA202190693A1 (ru) 2018-09-11 2021-07-27 Джуно Терапьютикс, Инк. Способы анализа масс-спектрометрии композиций модифицированных клеток
AU2019389151B2 (en) 2018-11-30 2025-07-24 Alpine Immune Sciences, Inc. CD86 variant immunomodulatory proteins and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
WO2020214957A1 (en) 2019-04-19 2020-10-22 Tcrcure Biopharma Corp. Anti-pd-1 antibodies and uses thereof
CN114025788A (zh) 2019-05-01 2022-02-08 朱诺治疗学股份有限公司 从经修饰的tgfbr2基因座表达重组受体的细胞、相关多核苷酸和方法
EP3986450A4 (en) 2019-06-20 2023-06-28 Memorial Sloan Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
CA3144070A1 (en) 2019-06-27 2020-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r175h or y220c mutation in p53
CN110357952B (zh) * 2019-07-17 2022-03-22 深圳市因诺转化医学研究院 识别人乳头瘤病毒hpv16-e7抗原的tcr
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
CN116034113A (zh) * 2019-12-30 2023-04-28 华夏英泰（北京）生物技术有限公司 一种增强型t细胞受体star及其应用
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
CN113072635B (zh) * 2020-01-06 2023-08-25 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的t细胞受体及其编码序列
US20240148869A1 (en) * 2020-05-07 2024-05-09 China Immunotech (Beijing) Biotechnology Co., Ltd Improved T cell receptor-costimulatory molecule chimera
CA3185145A1 (en) * 2020-05-25 2021-12-02 Bristar Immunotech Limited Enhanced synthetic t cell receptor and antigen receptor
US20230227526A1 (en) * 2020-06-09 2023-07-20 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
US20240216508A1 (en) 2020-06-26 2024-07-04 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
WO2022051449A2 (en) 2020-09-04 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r273c or y220c mutations in p53
WO2022060904A1 (en) * 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
EP4243937A2 (en) 2020-11-13 2023-09-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
CA3217263A1 (en) 2021-05-07 2022-11-10 The United States Of America, As Represented By The Secretary, Depart... T cell receptors recognizing c135y, r175h, or m237i mutation in p53
CN117897411A (zh) * 2021-06-30 2024-04-16 华夏英泰（北京）生物技术有限公司 一种多靶点合成t细胞受体抗原/抗体受体及其应用
CN116157528B (zh) * 2021-09-07 2025-07-22 北京可瑞生物科技有限公司 抗原结合蛋白及其用途
CN118265721A (zh) * 2021-10-18 2024-06-28 得克萨斯州大学系统董事会 靶向ndc80抗原的肽和经改造t细胞受体及使用方法
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
CA3237646A1 (en) * 2021-11-10 2023-05-19 Tscan Therapeutics, Inc. Binding proteins recognizing hpv16 e7 antigen and uses thereof
WO2023137471A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
US20250154503A1 (en) 2022-01-14 2025-05-15 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
EP4490173A1 (en) 2022-03-07 2025-01-15 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
CN115286698B (zh) * 2022-05-10 2023-09-01 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
JP2025531268A (ja) 2022-09-19 2025-09-19 チューン セラピューティクス インコーポレイテッド Ｔ細胞機能を調節するための組成物、システム、および方法
CN116731155B (zh) * 2022-09-21 2024-03-22 新景智源生物科技(苏州)有限公司 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途
CN121127261A (zh) 2023-03-27 2025-12-12 美国卫生和人力服务部 靶向p53中y220c或r175h突变的t细胞受体
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025096419A1 (en) * 2023-10-31 2025-05-08 Lyell Immunopharma, Inc. T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof
WO2025160480A1 (en) 2024-01-26 2025-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
WO2025193926A1 (en) 2024-03-15 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting e545k or n345k mutation in pik3ca
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131092A2 (en) * 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
CN102695717A (zh) * 2009-09-29 2012-09-26 Ucl商务股份有限公司 T细胞受体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IN165717B (OSRAM) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
CA2497552C (en) 2002-09-06 2014-05-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
CA2602463C (en) * 2005-04-01 2018-09-04 Avidex Ltd High affinity hiv t cell receptors
CA3016942C (en) 2007-05-31 2022-09-20 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
ES2745472T3 (es) 2013-07-15 2020-03-02 The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra Receptores de células T anti-virus del papiloma humano 16 E6
EP4609876A2 (en) * 2014-05-29 2025-09-03 The United States of America, as represented by the Secretary, Department of Health and Human Services Anti-human papillomavirus 16 e7 t cell receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131092A2 (en) * 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
CN102695717A (zh) * 2009-09-29 2012-09-26 Ucl商务股份有限公司 T细胞受体

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A Conserved E7-derived Cytotoxic T Lymphocyte Epitope Expressed on Human Papillomavirus 16-transformed HLA-A2+ Epithelial Cancers;Riemer A B 等;《Journal of Biological Chemistry》;20100917;第285卷(第38期);第29608-29622页 *
Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line;Sarah J. Youde 等;《Int. J. Cancer》;20050401;第114卷(第4期);第606-612页 *
Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens;Derin B. Keskin 等;《Front. Immunol.》;20111231;第2卷;第1-26页 *
Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer;Scholten K B J 等;《Clinical Immunology》;20050228;第114卷(第2期);摘要，120页右栏第2段 *
Promiscuous Behavior of HPV16E6 Specific T Cell Receptor Beta Chains Hampers Functional Expression in TCR Transgenic T Cells, Which Can Be Restored in Part by Genetic Modification;Kirsten B.J. Scholten 等;《Cellular Oncology 》;20100101;第32卷(第1-2期);第43-56页 *
Scholten K B J 等.Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.《Clinical Immunology》.2005,第114卷(第2期), *

Also Published As

Publication number Publication date
JP6997267B2 (ja) 2022-02-04
DK3149031T3 (da) 2020-03-16
US20210130432A1 (en) 2021-05-06
SA516380394B1 (ar) 2021-01-05
US20170145070A1 (en) 2017-05-25
AU2023200608B2 (en) 2024-08-22
AU2023200608A1 (en) 2023-03-09
BR112016027805A2 (pt) 2017-10-24
EP4609876A2 (en) 2025-09-03
AU2021202227A1 (en) 2021-05-06
AU2021202227B2 (en) 2022-11-10
EP3689900B1 (en) 2025-07-23
JP7744479B2 (ja) 2025-09-25
HRP20200376T1 (hr) 2020-08-07
PT3149031T (pt) 2020-03-25
US11434272B2 (en) 2022-09-06
AU2015266818B2 (en) 2019-10-03
WO2015184228A1 (en) 2015-12-03
CN113150112A (zh) 2021-07-23
LT3149031T (lt) 2020-05-25
IL248797A0 (en) 2017-01-31
IL248797B (en) 2021-05-31
KR102445667B1 (ko) 2022-09-21
CY1122790T1 (el) 2021-05-05
KR20220130267A (ko) 2022-09-26
KR20170003939A (ko) 2017-01-10
JP7535158B2 (ja) 2024-08-15
IL290655B1 (en) 2024-01-01
AU2019283892A1 (en) 2020-01-23
JP2024156861A (ja) 2024-11-06
JP6742991B2 (ja) 2020-08-19
MX2016015383A (es) 2017-02-28
AU2019283892B2 (en) 2021-01-28
CN113150112B (zh) 2024-02-06
ES2784237T3 (es) 2020-09-23
JP2022058360A (ja) 2022-04-12
JP7291196B2 (ja) 2023-06-14
JP2021000089A (ja) 2021-01-07
MX375379B (es) 2025-03-06
AU2015266818A1 (en) 2016-11-24
SI3149031T1 (sl) 2020-07-31
JP2023110036A (ja) 2023-08-08
US10870687B2 (en) 2020-12-22
EP3149031A1 (en) 2017-04-05
US20190085047A1 (en) 2019-03-21
PL3149031T3 (pl) 2020-08-24
IL290655B2 (en) 2024-05-01
MX2020010035A (es) 2020-10-14
EP3689900A1 (en) 2020-08-05
IL282518B (en) 2022-04-01
IL290655A (en) 2022-04-01
CA2950192A1 (en) 2015-12-03
US20220372103A1 (en) 2022-11-24
CN106661098A (zh) 2017-05-10
SMT202000143T1 (it) 2020-05-08
EP3149031B1 (en) 2019-12-18
IL282518A (en) 2021-06-30
US10174098B2 (en) 2019-01-08
AU2024266702A1 (en) 2024-12-12
JP2017524372A (ja) 2017-08-31
KR102618267B1 (ko) 2023-12-27

Similar Documents

Publication Publication Date Title
AU2021202227B2 (en) Anti-human papillomavirus 16 E7 T cell receptors
KR102569842B1 (ko) 키메라 항원 수용체-변형된 nk-92 세포
AU2014211454B2 (en) High avidity binding molecules recognizing MAGE-A1
CN107573419A (zh) 一种增强t细胞抗肿瘤活性的核酸分子
US20040208850A1 (en) Modified vaccinia ankara expressing p53 in cancer immunotherapy
TW202332690A (zh) 用於使用融合蛋白之ｔｃｒ重編程的組合物及方法
JP2018531014A6 (ja) 抗ｃｄ３０キメラ抗原受容体
JP2018531014A (ja) 抗ｃｄ３０キメラ抗原受容体
US20020147326A1 (en) Hexameric fusion proteins and uses therefor
KR101078202B1 (ko) 재조합 루브리신 분자 및 이의 용도
KR20180043841A (ko) 키메라 항원 수용체 및 이의 용도
KR20220139924A (ko) 큰 유전자 벡터 및 그의 전달 및 용도
CN106591371A (zh) Cd16a/gpc3双抗慢病毒表达载体及其构建方法和应用
CN108913718A (zh) 一种靶向EGFR vⅢ的CAR-T细胞的制备方法及应用
CN108103088B (zh) 重组GLP-1类似物Fc融合蛋白的优化基因及其应用
EP0975355A2 (en) Hexameric fusion proteins and uses therefor
KR20210137427A (ko) Car t 세포 방법 및 작제물
CN109652381A (zh) 基于碱基编辑靶向cd133的car-t细胞制备方法及应用
HK40056926A (en) Anti-human papillomavirus 16 e7 t cell receptors
HK40056926B (zh) 抗人乳头瘤病毒16e7 的t细胞受体
CN114891115B (zh) 一种car细胞疗法用核酸构建体及其慢病毒载体、细胞制剂和应用
CN109022363A (zh) 一种基于PiggyBac载体的CD-133-CAR-T系统构建方法
US20220135971A1 (en) Core master regulators of glioblastoma stem cells
CN117377683A (zh) 新抗原肽及其在治疗braf基因突变相关疾病中的用途
RU2726541C1 (ru) Рекомбинантная клеточная линия рака молочной железы человека BrCCh4e-134, экспрессирующая простат-специфический мембранный антиген человека

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant